Search Within

Heather Jolie Landau

Formats
  1. Meeting Abstract (281)
  2. Journal Article (127)
  3. Research Letter (15)
  4. Book Section (5)
  5. Review (3)
  6. Correspondence (2)
  7. Conference Paper (1)
  8. Editorial (1)
  9. Guidelines (1)
Groups
  1. Bone Marrow Transplant (436)
  2. Center for Hematologic Malignancies (436)
  3. Department of Medicine (436)
  4. Hematologic Malignancies, Division of (436)
  5. Survivorship Research (436)
  6. Myeloma (249)

More Groups

People
  1. Sergio Giralt (263)
  2. Hani Hassoun (224)
  3. David Chung (207)
  4. Alexander Lesokhin (187)
  5. Gunjan Shah (164)
  6. Sham Mailankody (147)

More People

Years
  1. 2025 (14)
  2. 2024 (51)
  3. 2023 (48)
  4. 2022 (42)
  5. 2021 (25)
  6. 2020 (34)

More Years

Publications
  1. Blood (154)
  2. Clinical Lymphoma, Myeloma and Leukemia (53)
  3. Biology of Blood and Marrow Transplantation (48)
  4. Journal of Clinical Oncology (24)
  5. Bone Marrow Transplantation (12)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (166)
  2. Elsevier Inc. (111)
  3. Nature Publishing Group (30)
  4. American Society of Clinical Oncology (25)
  5. Taylor & Francis Group (21)
  6. Ferrata Storti Foundation (8)

More Publishers

Results (436)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A Phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated al amyloidosis (SWOG S1702; NCT#03499808)
    Meeting Abstract

    Parker, T. L.; Rosenthal, A.; Sanchorawala, V.; Landau, H. J.; Campagnaro, E.; Kapoor, P.; Neparidze, N.; Hagen, P.; Sarosiek, S.; Scott, E. C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Meeting Abstract

    Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • TCR repertoires in graft-versus-host-disease (GVHD)-target tissues reveals tissue specificity of the alloimmune response
    Meeting Abstract

    DeWolf, S.; Nichols, K.; Nguyen, C. L.; Giardina, P. A.; Slingerland, J. B.; Elias, H.; Kappangantula, R.; Baez, P.; Murali, R.; Hayashi, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis
    Journal Article

    Chuy, K. L.; Drill, E.; Yang, J. C.; Landau, H.; Hassoun, H.; Nahhas, O.; Chen, C. L.; Yu, A. F.; Steingart, R. M.; Liu, J. E.
    JACC: CardioOncology (2020)

    Fulltext@MSK | Save
  • Prognostic factors for postrelapse survival after ex vivo CD34(+)-selected (T cell-depleted) allogeneic hematopoietic cell transplantation in multiple myeloma
    Journal Article

    Gomez-Arteaga, A.; Shah, G. L.; Baser, R. E.; Scordo, M.; Ruiz, J. D.; Bryant, A.; Dahi, P. B.; Ghosh, A.; Lahoud, O. B.; Landau, H. J.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial
    Meeting Abstract

    Kastritis, E.; Dispenzieri, A.; Wechalekar, A. D.; Schonland, S. O.; Kim, K.; Sanchorawala, V.; Landau, H. J.; Kwok, F.; Suzuki, K.; Comenzo, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save